Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2011
Date:11/7/2011

CARLSBAD, Calif., Nov. 7, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2011.  The Company finished the third quarter of 2011 with a pro forma net operating loss (NOL) of $20.0 million and $44.9 million for the three and nine months ended September 30, 2011, respectively, compared to a pro forma NOL of $6.0 million and $23.1 million for the same periods in 2010.  The Company finished the third quarter of 2011 with nearly $365 million in cash.  

"Our most notable success this year has been the submission of the Kynamro™ marketing authorization application to the European Medicines Agency.  With this submission, we are one step closer to commercializing Kynamro for patients who are at great risk of dying from their cardiovascular disease.  Genzyme remains on track to submit the U.S. application for marketing approval in the fourth quarter and is actively preparing to launch Kynamro next year in the U.S. and Europe.  Kynamro represents the first major commercial opportunity for Isis, and we are looking forward to its potential launch next year," said B. Lynne Parshall, J.D., Chief Operating Officer, Chief Financial Officer and Secretary of Isis.  "Together with Genzyme, we are initiating our next Kynamro study, FOCUS FH, this year, which is intended to support an expansion of the market for Kynamro for severe forms of hypercholesterolemia.  We and Genzyme are committed to continuing investments in this novel medicine to make it available to as many patients as appropriate to treat their severe and fatal cardiovascular disease."

Upcoming Key Milestones

  • File for marketing approval for Kynamro™ (mipomersen) in the United States in the fourth quarter of 2011 for patients with homozygous Familial Hypercholesterolemia (FH
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
    2. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
    3. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
    4. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
    5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
    6. Cambrex Reports Third Quarter 2011 Results
    7. Dyadic International Reports 2011 Third Quarter Financial Results
    8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
    9. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
    10. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
    (Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
    (Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
    Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
    ... 2007 - Geron,Corporation (Nasdaq:GERN) today announced the ... company's human,embryonic stem cell (hESC)-based therapeutic for ... direct attack by the human immune,system., Presented ... Federation of,Clinical Immunology Societies meeting in San ...
    ... BETHESDA, Md., June 11, 2007--New research supported ... of Arthritis and,Musculoskeletal and Skin Diseases (NIAMS) ... which is used for certain,types of seizures, ... pain and,other symptoms associated with the common, ...
    Cached Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
    (Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
    (Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
    (Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
    (Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
    (Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
    Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
    ... researchers have identified an unexpected molecular marker that ... to chemotherapy. Triple-negative breast cancers --which do ... progesterone receptor and do not have Her2/neu overexpression ... of the disease and cannot be treated with ...
    ... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early stage prostate cancer, those who have the prostate gland ... a "watchful waiting" approach, according to a new long-term study ... to be practice-changing, said Dr. Richard E. Greenberg, chief of ...
    ... Gardner HealthDay Reporter , WEDNESDAY, May 4 ... was able to rectify ventricular fibrillation, a severely abnormal ... none experienced sudden death, according to new research. ... is already approved in Europe and is undergoing review ...
    ... May issue of the journal Health Affairs , Mount ... of toxic chemicals and air pollutants in the environment, and ... also those already on the market. Leonardo Trasande, ... Sinai School of Medicine, analyzed the costs of conditions ...
    ... MOINES, Iowa, May 4, 2011 The Donald Danforth Plant ... from the Howard G. Buffett Foundation to bring healthier sorghum ... help fund the completion of the development of biofortified sorghum, ... upon sorghum as their staple diet. DuPont business Pioneer ...
    ... Translational Genomics Research Institute (TGen) has licensed its first ... modifying the actions of proteins. Today,s announcement is ... laboratory discoveries more rapidly into therapeutics that can immediately ... drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings ...
    Cached Medicine News:Health News:Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 3Health News:New Defibrillator Shows Promise in Small Study 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:TGen licenses first drug for patient use in clinical care 2
    Inquire...
    ... incubators,Two refrigerated incubators that are ... life cycle,testing. Microprocessor controlled heating ... display. High/low audible and visual ... internal chamber safety thermostat,provides over-temperature ...
    Inquire...
    Inquire...
    Medicine Products: